title: Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
abstract: BACKGROUND
  The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined.
  
  
  METHODS
  Thirty-four patients with refractory or relapsed NHL were treated with IDEA.
  
  
  RESULTS
  The overall remission and complete remission rates were 67.6% and 35.3%, respectively. The toxicity of IDEA was tolerable. With a median follow-up of 14 months, one-year overall survival (OS) and progression-free survival rates were 75.1% and 43.7%, respectively. Adequate numbers of CD34(+) cells were obtained in 77.8% of the patients assigned to receive autologous peripheral blood stem cell (PBSC) transplantation. High-dose chemotherapy with autologous PBSC transplantation was carried out in 14 patients; their 3-year OS was 75.0%, with a median follow-up of 38 months.
  
  
  CONCLUSIONS
  IDEA is an effective second-line chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.
authors.affiliation: Division of Hematology and Oncology, Okayama University Hospital, Shikata-cho 2-5-1, Okayama city, Okayama 700-8558, Japan. n-mori@md.okayama-u.ac.jp
authors.forename: Hisakazu
authors.initials: H
authors.lastname: Nishimori
authors.forename: Nobuharu
authors.initials: N
authors.lastname: Fujii
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Maeda
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Matsuoka
authors.forename: Katsuto
authors.initials: K
authors.lastname: Takenaka
authors.forename: Katsuji
authors.initials: K
authors.lastname: Shinagawa
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ikeda
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Mine
authors.initials: M
authors.lastname: Harada
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016879:Salvage Therapy
chemical_list: D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D007069:Ifosfamide